Background: Development of a nanosized polymeric delivery system for erlotinib was the main objectiveof this research. Materials and Methods: Poly caprolactone-polyethylene glycol-polycaprolactone (PCEC)copolymers with different compositions were synthesized via ring opening polymerization. Formation of triblockcopolymers was confirmed by HNMR as well as FT-IR. Erlotinib loaded nanoparticles were prepared by meansof synthesized copolymers with solvent displacement method. Results: Physicochemical properties of obtainedpolymeric nanoparticles were dependent on composition of used copolymers. Size of particles was decreased withdecreasing the PCL/PEG molar ratio in used copolymers. Encapsulation efficiency of prepared formulationswas declined by decreasing their particle size. Drug release behavior from the prepared nanoparticles exhibiteda sustained pattern without a burst release. From the release profiles, it can be found that erlotinib release ratefrom polymeric nanoparticles is decreased by increase of CL/PEG molar ratio of prepared block copolymers.Based on MTT assay results, cell growth inhibition of erlotinib has a dose and time dependent pattern. After 72hours of exposure, the 50% inhibitory concentration (IC50) of erlotinib hydrochloride was appeared to be 14.8μM. Conclusions: From the obtained results, it can be concluded that the prepared PCEC nanoparticles in thisstudy might have the potential to be considered as delivery system for erlotinib.
(2014). Synthesis, Characterization and in vitro Anti-Tumoral Evaluation of Erlotinib-PCEC Nanoparticles. Asian Pacific Journal of Cancer Prevention, 15(23), 10281-10287.
MLA
. "Synthesis, Characterization and in vitro Anti-Tumoral Evaluation of Erlotinib-PCEC Nanoparticles". Asian Pacific Journal of Cancer Prevention, 15, 23, 2014, 10281-10287.
HARVARD
(2014). 'Synthesis, Characterization and in vitro Anti-Tumoral Evaluation of Erlotinib-PCEC Nanoparticles', Asian Pacific Journal of Cancer Prevention, 15(23), pp. 10281-10287.
VANCOUVER
Synthesis, Characterization and in vitro Anti-Tumoral Evaluation of Erlotinib-PCEC Nanoparticles. Asian Pacific Journal of Cancer Prevention, 2014; 15(23): 10281-10287.